Spyre Therapeutics, Inc.
SYRE · XNASCIK 1636282fmd_0FA2NSSQYK2ZDY8GV9FJTWMSJVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 5 | 4 | 0 | 0 | 19 | 2 | 1 | 0 | 0 |
| Research and development | 18 | 23 | 37 | 65 | 60 | 57 | 59 | 90 | 163 | 172 |
| Total operating expenses | 27 | 33 | 49 | 80 | 81 | 84 | 87 | 243 | 209 | 210 |
| Operating income | (22) | (28) | (45) | (80) | (81) | (66) | (85) | (242) | (209) | (210) |
| Other non-operating income (expense) | 0 | 0 | 1 | 2 | 1 | (0) | 1 | (97) | 1 | 54 |
| Income before taxes | – | – | – | (78) | (81) | (66) | (84) | (339) | (208) | (155) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (0) | 0 | (0) |
| Net income from continuing operations | – | – | – | (78) | (81) | (66) | (84) | (339) | (208) | (155) |
| Net income | (22) | (27) | (44) | (78) | (81) | (66) | (84) | (339) | (208) | (155) |
| Net income to common shareholders | (22) | (27) | – | – | – | – | – | – | – | – |